12390 EL CAMINO REAL, SAN DIEGO, CA
Annual Report to Security Holders
Appoints David Ramsay as Interim Chief Financial Officer
Financial Results, Press Release
Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Performance-Based PSU Grant for CEO Dr. Helen Torley Approved
James Lang Elected to Board of Directors at Halozyme Therapeutics
CFO Transition Plan Announced for Nicole LaBrosse at Halozyme
Halozyme Therapeutics Completes $1.5 Billion Convertible Notes Offering
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party